IDYA IDEAYA Biosciences Inc.

20.35
+0.77  (+4%)
Previous Close 19.58
Open 19.72
52 Week Low 2.95
52 Week High 21.38
Market Cap $654,855,043
Shares 32,179,609
Float 22,410,686
Enterprise Value $342,068,143
Volume 106,629
Av. Daily Volume 211,487
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
IDE196 (basket)
Solid tumors
Phase 2
Phase 2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
IDE196 and binimetinib
Metastatic uveal melanoma (MUM)
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
IDE397
Solid tumors
Phase 1
Phase 1
Phase 1 trial to be initiated 1Q 2021.
IDE196 and crizotinib
Metastatic uveal melanoma (MUM)
Phase 1
Phase 1
Phase 1 trial initiation announced January 5, 2021.
IDE196
Uveal Melanoma
Phase 1
Phase 1
Phase 1 trial ongoing - one complete response confirmed October 31, 2019.

Latest News

  1. SOUTH SAN FRANCISCO, Calif., March 1, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the following upcoming investor relations events.

    Investor Relations Events

    • H.C. Wainwright Global Life Sciences Conference 2021 (Virtual)

      Corporate Presentation

      Tuesday, March 9th, 2021 at 7:00 am ET
    • Citi's 2021 Winter West Coast Biotech Virtual Bus Tour (Virtual)

      Fireside Chat with Analyst Mohit Bansal

      Tuesday, March 16th, 2021 at 3:00 pm ET
    • Oppenheimer's 31st Annual Healthcare Conference (Virtual)

      Company Presentation

      Wednesday, March 17th, 2021 at 2:30 pm ET
    • Roth 33rd Annual Conference (Virtual)

      Company Panel hosted by Analyst Zegbeh Jallah: "Highly Attractive Small Molecule

      Oncology Platforms" with Arvinas, IDEAYA Biosciences and Turning Point Therapeutics

      Wednesday, March 17th, 2021 at 5:00 pm ET

    A live audio webcast of selected events will be available by visiting the "Investors/News and Events/Investor Calendar" section of the IDEAYA website at https://ir.ideayabio.com/news-events/investor-calendar.  A replay of selected webcasts will be available for 30 days following the live event.

    About IDEAYA Biosciences

    IDEAYA is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.  IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies.  IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets. 

    Forward-Looking Statements

    This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's recent Quarterly Report on Form 10-Q filed on November 12, 2020 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/ideaya-to-participate-in-upcoming-march-2021-investor-relations-events-301236947.html

    SOURCE IDEAYA Biosciences, Inc.

    View Full Article Hide Full Article
  2. SOUTH SAN FRANCISCO, Calif., Feb. 22, 2021 /PRNewswire/ --IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced IDEAYA's inaugural Synthetic Lethality Investor Day, with scientific presentations from IDEAYA, GlaxoSmithKline (GSK) and several Key Opinion Leaders, will be held virtually on Tuesday, April 20, 2021, at 1:00 pm - 3:00 pm ET / 10:00 am - 12:00 pm PT.

    Scientific Presenters / Participants will include:

    IDEAYA Biosciences:

    Michael Dillon, Ph.D., Senior Vice President, Chief Scientific Officer

    Mark Lackner, Ph.D., Senior Vice President, Head of Biology and Translational Sciences

    Matt Maurer, M.D., Vice President, Head of Clinical Oncology and Medical Affairs

    GlaxoSmithKline:

    Benjamin Schwartz, Ph.D., Vice President, Head of Oncology Synthetic Lethality Research Unit

    Key Opinion Leaders / IDEAYA Scientific Advisors:

    -  Alan D'Andrea, M.D., Director, Center of DNA Damage and Repair, Dana Farber Cancer Institute of Harvard Medical School

    William Sellers, M.D., Core Institute Member and Director of the Cancer Program of the Broad Institute of MIT and Harvard

    The agenda will focus on IDEAYA/GSK partnered and IDEAYA wholly-owned Synthetic Lethality programs, including IDE397, a potential best-in-class methionine adenosyltransferase 2A (MAT2A) inhibitor being evaluated in a Phase 1 clinical trial targeting methylthioadenosine phosphorylase (MTAP) deletion, which is prevalent in approximately 15% of all solid tumors. Agenda topics will also include poly(ADP-ribose) gylcohydrolase (PARG), a potential first-in-class wholly-owned program, and the IDEAYA / GSK partnered Polymerase Theta (Pol Theta) program. A Development Candidate is targeted for each of the PARG and PolTheta programs in 2021.  

    Agenda Topics:

    -  Synthetic Lethality: An Emerging Area within Precision Medicine and GSK-IDEAYA Partnership

    -  IDE397 Phase 1 Program: Targeting MAT2A in MTAP-Deleted Tumors

    -  Werner Helicase: Compelling Synthetic Lethality Target

    -  Pol Theta: Key Target in MMEJ DNA Damage Repair Pathway

    -  PARG: Novel Target in Clinically Validated Pathway

    "We believe IDEAYA's inaugural Synthetic Lethality Investor Day with presenters from IDEAYA, GSK and several academic luminaries in the field will be an exciting forum for the scientific, analyst, and investor communities. We will discuss key biological insights for several potential first-in-class targets, including PARG, Pol Theta, and Werner Helicase, as well as the competitive differentiation and clinical development plan of IDE397, a Phase 1 MAT2A inhibitor pursuing the MTAP-deletion patient population," said Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences.  

    Additional information on the IDEAYA Synthetic Lethality Investor Day and registration for the event is available on IDEAYA's website at https://ir.ideayabio.com/events.

    About IDEAYA Biosciences

    IDEAYA is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets. 

    Forward-Looking Statements

    This press release contains forward-looking statements, including, but not limited to, statements related to (i) potential first-in-class and best-in-class status, (ii) the timing, content and participants of  the Synthetic Lethality Investor Day, and (iii) the competitive differentiation of IDE397. Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, IDEAYA's ability to successfully establish, protect and defend its intellectual property, the effects on IDEAYA's business of the worldwide COVID-19 pandemic, and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's recent Quarterly Report on Form 10-Q filed on November 12, 2020 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.   

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inaugural-synthetic-lethality-investor-day-301231992.html

    SOURCE IDEAYA Biosciences, Inc.

    View Full Article Hide Full Article
  3. SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the appointment of Susan Kelley, M.D., to its Board of Directors.  

    Dr. Kelley brings over 25 years of experience in oncology drug research and development to IDEAYA. Most recently she served as Chief Medical Officer of the Multiple Myeloma Research Consortium (MMRC) where she led the strategic design and management of clinical trials in North America. Prior to the MMRC, she held positions of increasing responsibility at Bayer Healthcare Pharmaceuticals and Bayer-Schering Pharma, including Vice President, Global Clinical Development and Therapeutic Area Head – Oncology, where she led the team responsible for the development and worldwide regulatory approval of Nexavar® (sorafenib). Prior to joining Bayer, Dr. Kelley worked at Bristol-Myers Squibb in Oncology and Immunology drug development, ultimately serving as Executive Director, Oncology Clinical Research, at the Bristol-Myers Squibb Pharmaceutical Research Institute. She serves or has served as a member of the Board of Directors at multiple publicly traded companies including Deciphera Pharmaceuticals, Daré Bioscience, VBL Therapeutics Ltd, ArQule and Immune Design. Dr. Kelley received her M.D. from Duke University School of Medicine. She was a Fellow in Medical Oncology and Clinical Fellow in Medicine at Dana-Farber Cancer Institute, Harvard Medical School, and a Fellow in Medical Oncology and Pharmacology at Yale University School of Medicine, where she also served as a Clinical Assistant Professor of Medicine.

    "Susan's expertise in clinical oncology will be invaluable as we advance the Phase 1 IDE397 program in MTAP-deletion, evaluate potential Phase 2 expansion for the IDE196 / binimetinib combination, and target to select a Development Candidate for the potential first-in-class PARG Synthetic Lethality program this year," said Yujiro S. Hata, President and Chief Executive Officer, at IDEAYA Biosciences. 

    "I am excited to join IDEAYA as the company advances a broad preclinical and clinical stage precision medicine oncology pipeline, including several potential first-in-class Synthetic Lethality programs with compelling biomarker hypotheses, and the kinase inhibitor IDE196, an area in which I gained clinical experience through the development of various kinase inhibitors, including Nexavar®," said Dr. Kelley.   

    About IDEAYA Biosciences

    IDEAYA is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.  IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies.  IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets. 

    Forward-Looking Statements

    This press release contains forward-looking statements, including, but not limited to, statements related to (i) the advancement of IDE397, (ii) the timing for selection of a development candidate for PARG, and (iii) the potential first-in-class and best-in-class status of programs.  Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, IDEAYA's ability to successfully establish, protect and defend its intellectual property, the effects on IDEAYA's business of the worldwide COVID-19 pandemic, and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's recent Quarterly Report on Form 10-Q filed on November 12, 2020 and any current and periodic reports filed with the U.S. Securities and Exchange Commission. 

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/ideaya-biosciences-appoints-susan-l-kelley-md-an-industry-veteran-in-medical-oncology-and-clinical-development-to-its-board-of-directors-301229557.html

    SOURCE IDEAYA Biosciences, Inc.

    View Full Article Hide Full Article
  4. SOUTH SAN FRANCISCO, Calif., Feb. 8, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the effectiveness of the Investigational New Drug (IND) application for a Phase 1 clinical trial to evaluate IDE397, a potential best-in-class methionine adenosyltransferase 2a (MAT2A) inhibitor. 

    IDE397 is IDEAYA's most advanced synthetic lethality program, and being developed in the clinic for cancer patients harboring methylthioadenosine phosphorylase (MTAP) deletion, which is prevalent in approximately 15% of all solid tumors.  IDEAYA is targeting a Q1 2021 First-Patient-In for the Phase 1 clinical trial of IDE397 in patients having solid tumors harboring MTAP deletion.

    IDEAYA also announced that Matthew Maurer, M.D., has joined the company as Vice President, Head of Clinical Oncology and Medical Affairs.  "Matt brings extensive clinical development and oncology experience in both the pharmaceutical industry and academia. His background in clinical oncology will be invaluable as we advance IDE397 clinically in MTAP-deletion and target to select the Development Candidate for our wholly-owned PARG program in 2021," said Yujiro S. Hata, President and Chief Executive Officer at IDEAYA Biosciences.

    Dr. Maurer has over 15 years of experience in oncology and previously worked at Bristol Myers Squibb (BMS) where he most recently led the clinical development of nivolumab and ipilimumab late phase studies in renal cell carcinoma and prostate cancer.  Prior to BMS, Dr. Maurer was a physician investigator and Assistant Professor of Medicine at Columbia University College of Physicians and Surgeons, where he served as a breast cancer specialist.  Dr. Maurer obtained his undergraduate degree from Princeton University and his medical degree from Mount Sinai School of Medicine, and then completed his residency at Columbia University Medical Center. 

    "I am thrilled to join the IDEAYA team and look forward to advancing the IDE397 clinical program and the broader Synthetic Lethality pipeline, including the PARG program, which has a potential application in breast cancer, an indication in which I have clinical experience as an oncologist," said Matthew Maurer, M.D., Vice President, Head of Clinical Oncology and Medical Affairs at IDEAYA Biosciences.

    An updated corporate presentation is available on IDEAYA's website at the Investor Relations page. See: https://ir.ideayabio.com/.

    About IDEAYA Biosciences

    IDEAYA is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.  IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies.  IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets. 

    Forward-Looking Statements

    This press release contains forward-looking statements, including, but not limited to, statements related to (i) the timing of the First-Patient-In for IDE397 Phase 1 study and (ii) potential applications of the PARG program.  Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, IDEAYA's ability to successfully establish, protect and defend its intellectual property, the effects on IDEAYA's business of the worldwide COVID-19 pandemic, and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's recent Quarterly Report on Form 10-Q filed on November 12, 2020 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.   

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/ideaya-announces-ide397-ind-clearance-by-us-fda-to-initiate-phase-1-and-appointment-of-matthew-maurer-md-as-vice-president-head-of-clinical-oncology-and-medical-affairs-301223379.html

    SOURCE IDEAYA Biosciences, Inc.

    View Full Article Hide Full Article
  5. SOUTH SAN FRANCISCO, Calif., Feb. 1, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced its participation at the following upcoming investor relations events.

    Investor Relations Events

    • Guggenheim Healthcare Talks 2021 Oncology Day (Virtual)

      Fireside Chat with Analyst Michael Schmidt

      Friday, February 12th, 2021 at 12:00 pm ET

       
    • LifeSci Partners Precision Oncology Event (Virtual)

      Company Presentation

      Wednesday, February 17th, 2021, at 2:00pm ET

    A live audio webcast of each presentation will be available by visiting the "Investors/News and Events/Investor Calendar" section of the IDEAYA website at https://ir.ideayabio.com/news-events/investor-calendar.  A replay of the webcasts will be available for 30 days following the live event.

    About IDEAYA Biosciences

    IDEAYA is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.  IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from the targeted therapies IDEAYA is developing.  IDEAYA is applying these capabilities across multiple classes of precision medicine, including synthetic lethality – which represents an emerging class of precision medicine targets. 

    Forward-Looking Statements

    This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's recent Quarterly Report on Form 10-Q filed on November 12, 2020 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/ideaya-to-participate-in-upcoming-february-2021-investor-relations-events-301218475.html

    SOURCE IDEAYA Biosciences, Inc.

    View Full Article Hide Full Article
View All IDEAYA Biosciences Inc. News